SUNNYVALE, Calif., July 7: Cepheid, a Danaher company and a leader in molecular diagnostics, today announced the publication of a study demonstrating the real-world impact of the Xpert Xpress MVP (multiplex vaginal panel) test when used at the point of care. The study showed that significantly more women with vaginitis symptoms (e.g., abnormal discharge, odor, itching, or discomfort) received appropriate treatment within 24 hours of their clinic visit when tested with Xpert Xpress MVP compared to standard diagnostic methods. Standard methods are still common in clinical practice and include symptom-based assessment and microscopy.
This study is the first randomized clinical trial to evaluate the utility of a multiplex molecular test for vaginitis at the point of care. The research was led by investigators at Magee-Womens Research Institute and the University of Pittsburgh and was supported by an investigator-initiated grant from Cepheid.
Key Study Findings
- 89.6% of women tested with Xpert Xpress MVP received appropriate treatment within 24 hours of their clinic visit compared to 51.9% with usual care (p < 0.001)
- Among symptomatic women confirmed with no infection, 50% in the usual care arm received unnecessary antimicrobial treatments compared to 27.1% in the Xpert Xpress MVP arm (p = 0.031)
- Most healthcare providers in the study with patients randomized to Xpert Xpress MVP were satisfied with the turnaround time and workflow
Limitations of Current Diagnostic Practices
Women presenting with vaginal infections with overlapping symptoms such as abnormal discharge, itching, or irritation are frequently treated based on nonspecific signs, visual assessment, or wet mount microscopy, which can be subjective.
This study provided insight into real-world diagnostic practices for vaginitis. The investigators reported that 25% of providers relied solely on symptoms to guide treatment decisions, and standard approaches correctly identified infections only about 50–63% of the time. These findings reinforce longstanding challenges associated with microscopy-based diagnosis, including inconsistent use and variable accuracy.
Significant Improvement in Appropriate Treatment
Overall, women tested with Xpert Xpress MVP were significantly more likely to receive appropriate treatment within 24 hours than those receiving usual care.
Findings also highlighted the risk of overtreatment in routine care. Among women with no detectable vaginal pathogens, 50.0% received inappropriate and unnecessary treatment with usual care compared to 27.1% of those tested with Xpert Xpress MVP.
"Overuse of antimicrobials when no pathogens are detected should be avoided since it can contribute to antimicrobial resistance, may disrupt the vaginal microbiome, may cause side effects and adds costs to women and their insurers," the study authors noted.
The majority of healthcare providers who experienced Xpert Xpress MVP reported positive perceptions of the test, with 87% indicating they would like to incorporate this type of testing into routine clinical practice.
Supporting Evidence-Based Care in Women's Health
Commenting on the findings, Connie Savor, MD, Chief Medical Officer at Cepheid, emphasized how access to rapid, on-demand molecular results can improve treatment decisions at the point of care.
"Women presenting with vaginal symptoms deserve accurate answers and timely, evidence-based care," said Dr. Savor. "This study demonstrates how molecular point-of-care tests, such as Xpert Xpress MVP, can help clinicians make more informed treatment decisions in a single visit, improving care while reducing unnecessary treatment."
Given that vaginal symptoms are often nonspecific and may occur in women without infection, the findings highlight the limitations of symptom-based management and the value of fast, accurate diagnostics at the point of care.